The Karolinska Institutet’s Academic Specialist Center (ASC) to Present Results of GeNeuro’s ProTEct-MS Phase 2 Study of Temelimab at ECTRIMS 2022

GENEVA--(BUSINESS WIRE)--Regulatory News:

GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced it will present Phase IIb safety and efficacy data on temelimab from its ProTEct-MS study at the 38^th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Amsterdam, Netherlands.

The trial was conducted at the Karolinska Institutet’s Academic Specialist Center in Stockholm, Sweden. The one-year Phase 2 trial evaluated the administration of temelimab in patients with relapsing remitting MS to address disease progression independent of relapses following treatment with rituximab.

As a reminder, the topline results of the Phase 2 ProTEct-MS study, communicated in March 2022, confirmed the excellent safety profile and tolerability of higher doses of temelimab and the synergistic potential to treat neurodegeneration in addition to anti-inflammatory therapy in multiple sclerosis. Efficacy data, obtained in patients already treated effectively for inflammation, showed that temelimab has a favorable impact on key MRI parameters measuring neurodegeneration.

The presentation, entitled “Primary analysis of ProTEct-MS, a randomized, placebo-controlled, phase 2 study of Temelimab for the prevention of neurodegeneration in rituximab-treated patients with relapsing multiple sclerosis,” will be made by Prof. Fredrik Piehl, Principal Investigator of the study, during the “Free Communications 5: Treatment” session on Thursday, October 27, 2022, at 3:30 pm CEST.

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.

For more information, visit: www.geneuro.com

Disclaimer:

This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.